12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Incivek regulatory update

FDA updated the label of Incivek telaprevir from Vertex to include a boxed warning that patients experiencing a rash with systemic symptoms or a progressive severe rash should immediately stop treatment of the HCV drug and peginterferon alfa and ribavirin....

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >